CelLBxHealth plc’s Parsortix® Platform Validated by Peer-Reviewed Study for Glioblastoma Detection and Monitoring

CelLBxHealth plc’s Parsortix® Platform Validated by Peer-Reviewed Study for Glioblastoma Detection and Monitoring →

CelLBxHealth plc (AIM: CLBX), a circulating tumour cell (CTC) intelligence company based in Guildford, has revealed the publication of an independent peer-reviewed study in JCO Precision Oncology endorsing its Parsortix® platform for detect…